<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Chagas <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> and <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischemic heart disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IHD</z:e>) are frequent causes of <z:hpo ids='HP_0011010'>chronic</z:hpo> systolic <z:hpo ids='HP_0001635'>heart failure</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e>) in areas where the former is endemic </plain></SENT>
<SENT sid="1" pm="."><plain>Nonetheless, a specific comparison of outcome and role of etiology of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> failure has not been performed in patients with both conditions </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Two-hundred twenty two patients with Chagas <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> and 79 with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IHD</z:e> with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> were included in the study </plain></SENT>
<SENT sid="3" pm="."><plain>A Cox proportional hazards model was used to establish independent predictors of mortality for the studied population </plain></SENT>
<SENT sid="4" pm="."><plain>Survival analysis was performed with the Kaplan-Meir product limit method </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: In the multivariable model, Beta-Blocker therapy [(hazard ratio (HR)=0.36; 95% confidence interval (CI) 0.24 to 0.52; p&lt;0.005)], Chagas etiology of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> (HR=3.6; 95% CI 2.0 to 6.5; p&lt;0.005), serum <z:chebi fb="199" ids="26708">sodium</z:chebi> levels (HR=0.95; 95% CI 0.91 to 0.98; p&lt;0.005), digoxin use (HR=2.1; 95% CI 1.19 to 3.80, p=0.01), and <z:chebi fb="0" ids="9241">spironolactone</z:chebi> use (HR=1.7; 95% CI 1.10 to 2.80; p=0.02) were determined independent predictors of <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality for this cohort </plain></SENT>
<SENT sid="6" pm="."><plain>Probability of survival at 12, 24, 36, 48, and 60months was 92%, 92%, 88%, 81%, and 78%, respectively, in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IHD</z:e> patients, and 79%, 61%, 49%, 41%, and 35%, respectively, in Chagas <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> patients (p&lt;0.005) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: Outcome in patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> systolic <z:hpo ids='HP_0001635'>heart failure</z:hpo> secondary to Chagas <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> is poorer than that seen in those with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IHD</z:e> </plain></SENT>
</text></document>